Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Improved therapeutic T cell

A therapeutic, cell-based technology, applied in the direction of genetically modified cells, animal cells, cells modified by introducing foreign genetic material, etc., can solve problems such as difficult to meet clinical needs and low co-expression efficiency

Pending Publication Date: 2020-03-06
IMMUNOTECH BIOPHARM CO LTD +1
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, there has been no report on the co-expression of CAR / TCR and DNRII in the same T cell for the treatment of tumors
This may be due to the low co-expression efficiency of the two proteins, which is difficult to meet clinical needs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Improved therapeutic T cell
  • Improved therapeutic T cell
  • Improved therapeutic T cell

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] Example 1. Optimization of lentiviral vectors for expressing CAR

[0071] The lentiviral vector used to transduce CAR should contain the desired CAR transgene and be able to express it in the cell. Two third-generation lentiviral vectors for CAR expression were designed, namely the old vector pPVLV1 ( figure 1 A) and the new vector pPVLV2 ( figure 1 B). pPVLV1 contains the 531 bp long human elongation factor 1 alpha (EF1 alpha) promoter and pPVLV1 contains the 212 bp truncated human EF1 alpha promoter. The various elements contained in the two vectors and their descriptions are found in Table 1 below.

[0072] The CAR to be expressed in the embodiment of the present application comprises scFv targeting CD19, hinge and transmembrane domain of human CD8, intracellular domain 4-1BB and CD3ζ. The amino acid of the CAR targeting CD19 is shown in SEQ ID NO:16, and the nucleotide sequence is shown in SEQ ID NO:8.

[0073] Table 1. Related elements on pPVLV1 and pPVLV2 len...

Embodiment 2

[0082] Example 2, promoter affects the transduction and expression of CAR gene

[0083] In order to further demonstrate the influence of different promoters, a pPVLV2-based image 3 Two CAR-luciferase reporter vectors, which differ only in the promoter driving the expression of the transgene, in which CAR-19 was cloned upstream of the P2A-Fluc (firefly luciferase) cassette, forming a bicistronic ( image 3 A and B).

[0084] After the vector is transduced into the cell, due to the presence of the coding sequence of the P2A self-cleaving peptide, two molecules, CAR-19 and luciferase, will be expressed in the same cell at a ratio of approximately 1:1, wherein the fluorescence intensity can be Reflects CAR-19 transduction efficiency (see image 3 C schematic diagram). image 3 D shows luciferase activity measured 48 hours after transduction of the two lentiviral vectors into 293T cells. The results show that with P EF1α The fluorescence of cells transduced with lentiviral ve...

Embodiment 3

[0086] Example 3, co-expression of CAR and DNRII in cells

[0087] TGF-β is an important T cell inhibitory factor, which may lead to the weakening or disappearance of the killing effect of therapeutic T cells on target cells. Clinically, TGF-β is widely expressed in a variety of tumor tissues and significantly inhibits the killing activity of tumor-specific T cells on tumor cells, which is an important reason for the failure of immunotherapy. The dominant negative TGF-β receptor type II (DNRII) is a negative regulatory receptor of TGF-β, which can inhibit the inhibitory effect of TGF-β on T cells. The following examples investigate the effect of co-expressing CAR and DNRII in T cells. The amino acid sequence of DNRII is shown in SEQ ID NO:17, and its nucleotide sequence is shown in SEQ ID NO:18.

[0088] First, similar to Example 2, a pPVLV2-based Figure 4 (A and B) Two CAR-19-DNRII vectors that differ only in the promoter driving transgene expression. Among them, CAR-19 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention, which belongs to the field of biological medicines, in particular, relates to an improved therapeutic T cell and a method of making the same. Specifically, according to the invention, co-expression of exogenous antigen-specific receptor protein (for example, TCR or CAR) and a dominant negative TGF-beta type II receptors in a T cell is realized by means of ransduction by a lentiviralvector and thus an improved therapeutic T cell ( a TCR-T or CAR-T cell) is prepared.

Description

technical field [0001] The invention belongs to the field of biomedicine. In particular, the present invention relates to improved therapeutic T cells and methods for their preparation. Specifically, the present invention relates to the transduction of lentiviral vectors to co-express exogenous antigen-specific receptor proteins and dominant-negative TGF-beta II receptors in T cells to prepare improved therapeutic T cells. [0002] Background of the invention [0003] T cells are key immune cells in the body that execute tumor cell killing and virus-infected cell killing. In recent years, the use of T cells, including antigen-specific T cells derived from in vitro induced or tumor-infiltrating lymphocytes, genetically modified chimeric antigen receptor T cells (CAR-T cells), genetically modified T cell receptor T cells (TCR-T cells) for the treatment of malignant tumors, in some clinical patients showed significant tumor clearance and control. However, due to the immune es...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/867C12N15/62C12N5/10A61K39/00A61P35/00A61P35/02
CPCC12N15/86C07K16/2803C07K14/71C07K14/7051C07K14/70578C07K14/70517C12N5/0636A61P35/00A61P35/02C12N2740/15043C12N2800/107C07K2317/622C07K2319/00C07K2319/03C07K2319/33C07K2319/74C12N2510/00A61K39/4631A61K39/4637A61K39/464412A61K39/4611C12N2740/16043C12N2830/48C12N2830/36C12N2830/15C12N2501/15C12N2501/515A61K48/00C07K2319/02C07K2317/53A61K39/001103A61K39/001111A61K39/001102
Inventor 王歈李贤秀郑南哲
Owner IMMUNOTECH BIOPHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com